Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  BCG solution
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-8 of 8 for your search:
Start Over
Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 12154, NCT01438112
URO-BCG-4 : Bladder Tumors Immunotherapy
Phase: Phase III
Type: Treatment
Status: Completed
Age: Not specified
Sponsor: Other
Protocol IDs: 2003/081/HP, NCT00213655
Mitomycin C Versus Bacillus Calmette-Guerin in the Intravesical Treatment of Non-Muscle-Invasive Bladder Cancer Patients
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: 09-118, NCT00974818
Phase III Randomized Study of Intravesical Mitomycin C and Bladder Hyperthermia Versus Intravesical Bacillus Calmette-Guerin (BCG) or Standard Therapy as Second-Line Therapy in Patients With Recurrent Non-Muscle Invasive Bladder Cancer After Induction or Maintenance BCG. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information.
Phase: Phase III
Type: Biomarker/Laboratory analysis, Health services research, Treatment
Status: Unknown
Age: 18 and over
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: CRC-TU-BL3010-HYMN, CRCTU-BL3010-HYMN, ISRCTN85785327, EUDRACT-2008-005428-99, EU-21015, UCL-08/0365, KYOWA-CRC-TU-BL3010-HYMN, MREC-09/H0717/56, NCT01094964
Study of Mycobacterium w in Superficial Transitional Cell Carcinoma of Bladder
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR-60/9150, NCT00694915
BCG Modulation of the recMAGE-A3 + AS15 ASCI Response in the Treatment of Non Muscle Invasive Bladder Cancer (NMIBC) Patients
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: URO-68/11, NCT01498172
Markers of Response to Intravesical Bladder Cancer Therapy
Phase: No phase specified
Type: Biomarker/Laboratory analysis
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: LAB05-0326, NCT01007058
Study of BCG + Aminophylline Toxicity When Used in the Treatment of Bladder Cancer
Phase: No phase specified
Type: Treatment
Status: Completed
Age: 40 and over
Sponsor: Other
Protocol IDs: 14585, NCT01240824
Start Over